NOSIP

Summary

NOSIP (nitric oxide synthase interacting protein, HGNC:17946) is a protein-coding gene on chromosome 19q13.33, encoding Nitric oxide synthase-interacting protein (Q9Y314). E3 ubiquitin-protein ligase that is essential for proper development of the forebrain, the eye, and the face.

The protein encoded by this gene may modulate the activity and localization of nitric oxide synthase (endothelial and neuronal) and thus nitric oxide production. Alternative splicing results in multiple transcript variants that encode the same protein.

Source: NCBI Gene 51070 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 53 total
• Druggable target: yes
• MANE Select transcript: NM_001270960

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17946
Approved symbol	NOSIP
Name	nitric oxide synthase interacting protein
Location	19q13.33
Locus type	gene with protein product
Status	Approved
Aliases	CGI-25
Ensembl gene	ENSG00000142546
Ensembl biotype	protein_coding
OMIM	616759
Entrez	51070

Gene structure

Transcript identifiers

Ensembl transcripts: 36 — 25 protein_coding, 8 retained_intron, 2 nonsense_mediated_decay, 1 non_stop_decay

ENST00000339093, ENST00000593345, ENST00000594932, ENST00000596358, ENST00000596477, ENST00000598296, ENST00000598544, ENST00000598550, ENST00000598820, ENST00000598839, ENST00000599425, ENST00000599537, ENST00000600019, ENST00000601015, ENST00000601107, ENST00000601340, ENST00000874162, ENST00000874163, ENST00000874164, ENST00000874165, ENST00000874166, ENST00000874167, ENST00000874168, ENST00000874169, ENST00000874170, ENST00000874171, ENST00000874172, ENST00000874173, ENST00000874174, ENST00000917073, ENST00000917074, ENST00000917075, ENST00000917076, ENST00000917077, ENST00000962184, ENST00000962185

RefSeq mRNA: 3 — MANE Select: NM_001270960 NM_001270960, NM_001363649, NM_015953

CCDS: CCDS12772, CCDS86789

Canonical transcript exons

ENST00000596358 — 9 exons

Exon	Start	End
ENSE00001377817	49580515	49580556
ENSE00003498090	49560622	49560692
ENSE00003499554	49559934	49560039
ENSE00003511709	49556875	49556993
ENSE00003562866	49558897	49558978
ENSE00003568480	49557090	49557249
ENSE00003631083	49556317	49556425
ENSE00003791537	49556549	49556736
ENSE00003896192	49555468	49555822

Expression profiles

Bgee: expression breadth ubiquitous, 287 present calls, max score 97.99.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 45.5923 / max 600.7309, expressed in 1824 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
182057	37.2294	1823
182054	2.4494	94
182058	2.4126	1446
182053	1.2812	727
182048	0.5428	133
182049	0.5056	77
182050	0.3527	61
182052	0.3217	99
182055	0.2422	64
182056	0.1698	66

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	97.99	gold quality
granulocyte	CL:0000094	97.96	gold quality
right testis	UBERON:0004534	97.85	gold quality
body of pancreas	UBERON:0001150	96.87	gold quality
triceps brachii	UBERON:0001509	96.77	gold quality
hindlimb stylopod muscle	UBERON:0004252	96.71	gold quality
blood	UBERON:0000178	96.63	gold quality
mucosa of transverse colon	UBERON:0004991	96.43	gold quality
tendon of biceps brachii	UBERON:0008188	96.19	gold quality
testis	UBERON:0000473	96.17	gold quality
gluteal muscle	UBERON:0002000	95.86	gold quality
gastrocnemius	UBERON:0001388	95.60	gold quality
muscle of leg	UBERON:0001383	95.57	gold quality
male germ cell	CL:0000015	95.37	gold quality
sperm	CL:0000019	95.32	gold quality
muscle organ	UBERON:0001630	95.28	gold quality
vastus lateralis	UBERON:0001379	95.08	gold quality
apex of heart	UBERON:0002098	94.99	gold quality
lymph node	UBERON:0000029	94.97	gold quality
pancreas	UBERON:0001264	94.95	gold quality
quadriceps femoris	UBERON:0001377	94.74	gold quality
spleen	UBERON:0002106	94.62	gold quality
lower esophagus mucosa	UBERON:0035834	94.29	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	94.26	gold quality
ectocervix	UBERON:0012249	94.15	gold quality
endocervix	UBERON:0000458	94.14	gold quality
amniotic fluid	UBERON:0000173	94.12	gold quality
right atrium auricular region	UBERON:0006631	94.10	gold quality
skeletal muscle tissue	UBERON:0001134	94.09	gold quality
transverse colon	UBERON:0001157	94.09	gold quality

Single-cell (SCXA)

Detected in 11 experiment(s), a significant marker in 7.

Experiment	Marker?	Max mean expression
E-HCAD-4	yes	736.71
E-MTAB-8911	yes	474.91
E-CURD-122	yes	102.42
E-CURD-88	yes	57.78
E-HCAD-1	yes	30.54
E-CURD-112	yes	9.27
E-MTAB-7606	no	2754.76
E-CURD-55	no	815.18
E-CURD-77	no	718.63
E-CURD-85	no	550.35
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

3 targeting NOSIP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4677-5P	99.70	70.09	1940
HSA-MIR-2116-5P	99.32	69.34	1273
HSA-MIR-6739-3P	99.22	68.84	1843

Literature-anchored findings (GeneRIF, showing 5)

• endothelial nitric oxide synthase (eNOS) interacting protein (NOSIP), modulator of eNOS activity by alteration of eNOS subcellular localisation; high expression levels in endothelial cells and vascularized tissue. (PMID:11149895)
• Endogenous NOSIP reduces the enzymatic capacity of eNOS, specifically in the G(2) phase of the cell cycle by targeting eNOS to the actin cytoskeleton. (PMID:16135813)
• While NOSIP expression was increased in Hirschsprung’s disease (HSCR) vs. non- HSCR patients, no significant difference was observed in patients with Hirschsprung’s associated enterocolitis. The increased expression of NOSIP in the aganglionic and ganglionic bowel of HSCR may contribute to the development of enterocolitis by inhibiting local nitric oxide production in patients with Hirschsprung’s disease. (PMID:28196663)
• nNOS induction and NOSIP interaction impact granulopoiesis and neutrophil differentiation by modulating nitric oxide generation. (PMID:33771575)
• Transportin 1 is a major nuclear import receptor of the nitric oxide synthase interacting protein. (PMID:36690276)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	nosip	ENSDARG00000037958
mus_musculus	Nosip	ENSMUSG00000003421
rattus_norvegicus	Nosip	ENSRNOG00000020543
drosophila_melanogaster	CG6179	FBGN0030915
caenorhabditis_elegans		WBGENE00019898

Protein

Protein identifiers

Nitric oxide synthase-interacting protein — Q9Y314 (reviewed: Q9Y314)

Alternative names: E3 ubiquitin-protein ligase NOSIP, RING-type E3 ubiquitin transferase NOSIP, eNOS-interacting protein

All UniProt accessions (7): Q9Y314, A0A075B6F9, A0A075B797, M0QX85, M0R1K2, M0R1T7, M0R3B2

UniProt curated annotations — full annotation on UniProt →

Function. E3 ubiquitin-protein ligase that is essential for proper development of the forebrain, the eye, and the face. Catalyzes monoubiquitination of serine/threonine-protein phosphatase 2A (PP2A) catalytic subunit PPP2CA/PPP2CB. Negatively regulates nitric oxide production by inducing NOS1 and NOS3 translocation to actin cytoskeleton and inhibiting their enzymatic activity.

Subunit / interactions. Interacts with NOS1 and NOS3. Interacts with PP2A holoenzyme, containing PPP2CA, PPP2CB, PPP2R1A and PPP2R2A subunits.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Expressed in heart, brain and lung. Present in endothelial cells (at protein level).

Domain organisation. The U-box-like region is a truncated U-box domain. It is unknown whether it is functional or not.

Similarity. Belongs to the NOSIP family.

RefSeq proteins (3): NP_001257889, NP_001350578, NP_057037 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR016818	NOSIP	Family
IPR031790	Znf-NOSIP	Domain

Pfam: PF15906

UniProt features (7 total): region of interest 2, modified residue 2, chain 1, short sequence motif 1, sequence variant 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
8C6J	ELECTRON MICROSCOPY	2.8
9FMD	ELECTRON MICROSCOPY	3.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y314-F1	82.04	0.47

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 36, 107

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-203754	NOSIP mediated eNOS trafficking

MSigDB gene sets: 206 (showing top): AREB6_01, GOBP_REGULATION_OF_OXIDOREDUCTASE_ACTIVITY, CAGCTG_AP4_Q5, GOBP_REGULATION_OF_NITRIC_OXIDE_SYNTHASE_ACTIVITY, GOBP_REACTIVE_NITROGEN_SPECIES_METABOLIC_PROCESS, GOBP_NEGATIVE_REGULATION_OF_OXIDOREDUCTASE_ACTIVITY, BLALOCK_ALZHEIMERS_DISEASE_UP, JAZAG_TGFB1_SIGNALING_VIA_SMAD4_UP, GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION, HP1SITEFACTOR_Q6, GOBP_NEGATIVE_REGULATION_OF_CATALYTIC_ACTIVITY, LIU_CMYB_TARGETS_UP, GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS, CETS1P54_01, OSMAN_BLADDER_CANCER_DN

GO Biological Process (5): negative regulation of catalytic activity (GO:0043086), regulation of nitric oxide biosynthetic process (GO:0045428), nitric oxide metabolic process (GO:0046209), negative regulation of nitric-oxide synthase activity (GO:0051001), protein ubiquitination (GO:0016567)

GO Molecular Function (6): RNA binding (GO:0003723), ubiquitin protein ligase activity (GO:0061630), molecular sequestering activity (GO:0140313), ubiquitin-protein transferase activity (GO:0004842), protein binding (GO:0005515), transferase activity (GO:0016740)

GO Cellular Component (5): Golgi membrane (GO:0000139), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Metabolism of nitric oxide: NOS3 activation and regulation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
catalytic activity	2
negative regulation of molecular function	1
regulation of catalytic activity	1
nitric oxide biosynthetic process	1
regulation of biosynthetic process	1
regulation of nitric oxide metabolic process	1
reactive nitrogen species metabolic process	1
nitric-oxide synthase activity	1
regulation of nitric-oxide synthase activity	1
negative regulation of oxidoreductase activity	1
protein modification by small protein conjugation	1
nucleic acid binding	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
molecular_function	1
ubiquitin-like protein transferase activity	1
binding	1
Golgi apparatus	1
bounding membrane of organelle	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

962 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NOSIP	NOS3	P29474	961
NOSIP	NOSTRIN	Q8IVI9	675
NOSIP	CAV1	Q03135	627
NOSIP	NOS1	P29475	538
NOSIP	PRRG2	O14669	523
NOSIP	DNM2	P50570	523
NOSIP	HSP90AA1	P07900	521
NOSIP	HSP90AB1	P08238	520
NOSIP	PRKG1	P14619	509
NOSIP	C9orf78	Q9NZ63	455
NOSIP	RCN3	Q96D15	452
NOSIP	NOS1AP	O75052	442
NOSIP	ERBB2	P04626	402
NOSIP	RPL13A	P40429	396
NOSIP	FAM20C	Q8IXL6	395

IntAct

32 interactions, top by confidence:

A	B	Type	Score
ZNF410	NOSIP	psi-mi:“MI:0915”(physical association)	0.560
NOSIP	TNNC2	psi-mi:“MI:0914”(association)	0.530
OTUB1		psi-mi:“MI:0914”(association)	0.350
OTUB1	EPM2A	psi-mi:“MI:0914”(association)	0.350
JUN		psi-mi:“MI:0914”(association)	0.350
JUN	TPM3	psi-mi:“MI:0914”(association)	0.350
HSCB	RBP5	psi-mi:“MI:0914”(association)	0.350
RRP1B	ZNF785	psi-mi:“MI:0914”(association)	0.350
CUL3	PXDNL	psi-mi:“MI:0914”(association)	0.350
POLL	SULT1C2	psi-mi:“MI:0914”(association)	0.350
NEU2	PEX14	psi-mi:“MI:0914”(association)	0.350
RASGRF2	SNRPA	psi-mi:“MI:0914”(association)	0.350
CEP135	MCRIP1	psi-mi:“MI:0914”(association)	0.350
CEP135	WWP2	psi-mi:“MI:0914”(association)	0.350
CEP135	WDR91	psi-mi:“MI:0914”(association)	0.350
CAPZB	ENAH	psi-mi:“MI:0914”(association)	0.350
S100P	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
HAP1	PPP1R12A	psi-mi:“MI:0914”(association)	0.350
LMNA	SMCHD1	psi-mi:“MI:2364”(proximity)	0.270
TP53BP1	PSMD14	psi-mi:“MI:2364”(proximity)	0.270
KLF16	SMCHD1	psi-mi:“MI:2364”(proximity)	0.270
HNRNPC	SBNO1	psi-mi:“MI:2364”(proximity)	0.270
PPIL4	ESYT2	psi-mi:“MI:2364”(proximity)	0.270
ZRANB2	SBNO1	psi-mi:“MI:2364”(proximity)	0.270
NPM1	SBNO1	psi-mi:“MI:2364”(proximity)	0.270
NOSIP	BCAR3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (136): NOSIP (Affinity Capture-MS), NOSIP (Affinity Capture-MS), NOSIP (Affinity Capture-MS), TNNC2 (Affinity Capture-MS), NOSIP (Affinity Capture-MS), HMCES (Co-fractionation), NOSIP (Co-fractionation), NOSIP (Co-fractionation), NOSIP (Co-fractionation), NOSIP (Affinity Capture-MS), NOSIP (Affinity Capture-MS), NOSIP (Affinity Capture-MS), PPP2CA (Affinity Capture-MS), PPP2CB (Affinity Capture-MS), PPP2R1A (Affinity Capture-MS)

ESM2 similar proteins: A6SGN8, A7EWN6, B4I9X1, B4NTY9, O43395, O60869, O60870, O64981, O70333, P10871, P10896, P31753, P93431, Q1WCC0, Q2KIA6, Q32LC9, Q3SWY5, Q3T0V7, Q3ZC66, Q40073, Q4R7H4, Q567Z6, Q5R5F1, Q5U5C5, Q5ZJ85, Q5ZKB6, Q5ZMC0, Q6F444, Q6FJN0, Q6NU28, Q6NVP6, Q6P829, Q792Q4, Q7SXM7, Q7ZTZ2, Q8BFR6, Q8CCF0, Q8ISQ3, Q8K339, Q8TCF1

Diamond homologs: Q21755, Q3SWY5, Q4R7H4, Q5U3S7, Q6NUH3, Q6P829, Q9D6T0, Q9VWV8, Q9Y314, Q9SY88, Q55DU4, Q2U5W8, Q4WVU5

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
NOSIP	“down-regulates quantity by destabilization”	PPP2CA	ubiquitination
NOSIP	“up-regulates activity”	EPOR	ubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

53 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	39
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2754 predictions. Top by Δscore:

Variant	Effect	Δscore
19:49556311:TCTTA:T	donor_loss	1.0000
19:49556312:CTTAC:C	donor_loss	1.0000
19:49556313:TTACC:T	donor_loss	1.0000
19:49556314:TAC:T	donor_loss	1.0000
19:49556315:A:AC	donor_gain	1.0000
19:49556315:AC:A	donor_gain	1.0000
19:49556315:ACC:A	donor_gain	1.0000
19:49556315:ACCCG:A	donor_gain	1.0000
19:49556316:C:CC	donor_gain	1.0000
19:49556316:CC:C	donor_gain	1.0000
19:49556316:CCC:C	donor_gain	1.0000
19:49556316:CCCG:C	donor_gain	1.0000
19:49556316:CCCGC:C	donor_gain	1.0000
19:49556421:CCCCA:C	acceptor_gain	1.0000
19:49556422:CCCA:C	acceptor_gain	1.0000
19:49556422:CCCAC:C	acceptor_gain	1.0000
19:49556423:CCA:C	acceptor_gain	1.0000
19:49556423:CCAC:C	acceptor_gain	1.0000
19:49556424:CA:C	acceptor_gain	1.0000
19:49556424:CAC:C	acceptor_gain	1.0000
19:49556426:C:CC	acceptor_gain	1.0000
19:49556438:C:T	acceptor_gain	1.0000
19:49556547:A:AC	donor_gain	1.0000
19:49556548:C:CT	donor_gain	1.0000
19:49556548:CG:C	donor_gain	1.0000
19:49556732:CGGGA:C	acceptor_gain	1.0000
19:49556733:GGGA:G	acceptor_gain	1.0000
19:49556734:GGA:G	acceptor_gain	1.0000
19:49556735:GA:G	acceptor_gain	1.0000
19:49556735:GACTG:G	acceptor_loss	1.0000

AlphaMissense

1937 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:49560024:C:T	G29E	1.000
19:49560638:C:A	E18D	1.000
19:49560638:C:G	E18D	1.000
19:49560652:A:G	Y14H	1.000
19:49560682:G:C	H4D	1.000
19:49555808:G:C	F283L	0.999
19:49555808:G:T	F283L	0.999
19:49555810:A:G	F283L	0.999
19:49556414:A:T	V246D	0.999
19:49556607:A:G	C223R	0.999
19:49556923:C:A	W163C	0.999
19:49556923:C:G	W163C	0.999
19:49556925:A:G	W163R	0.999
19:49556925:A:T	W163R	0.999
19:49556926:G:C	F162L	0.999
19:49556926:G:T	F162L	0.999
19:49556928:A:G	F162L	0.999
19:49558970:C:T	G62D	0.999
19:49559972:A:C	C46W	0.999
19:49559974:A:G	C46R	0.999
19:49559995:C:G	A39P	0.999
19:49560025:C:A	G29W	0.999
19:49560025:C:G	G29R	0.999
19:49560025:C:T	G29R	0.999
19:49560626:G:C	D22E	0.999
19:49560626:G:T	D22E	0.999
19:49560628:C:G	D22H	0.999
19:49560639:T:A	E18V	0.999
19:49560640:C:T	E18K	0.999
19:49560648:G:A	T15I	0.999

dbSNP variants (sampled 300 via entrez): RS1000145770 (19:49572268 G>C), RS1000148676 (19:49562154 T>C), RS1000256329 (19:49566342 C>T), RS1000273297 (19:49567254 C>T), RS1000332089 (19:49580610 C>T), RS1000542503 (19:49554972 G>A), RS1000546902 (19:49561241 T>C), RS1000834611 (19:49574844 C>T), RS1000883726 (19:49578734 C>T), RS1001051476 (19:49555690 G>A,T), RS1001089700 (19:49566524 C>T), RS1001200175 (19:49571069 T>C,G), RS1001352604 (19:49555482 C>A,T), RS1001481452 (19:49576975 G>T), RS1001661280 (19:49565194 C>T)

Disease associations

OMIM: gene MIM:616759 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST002539_91	Schizophrenia	5.000000e-08
GCST004601_194	Red blood cell count	8.000000e-12
GCST004604_44	Hematocrit	1.000000e-10
GCST008155_28	Waist-hip ratio	2.000000e-06
GCST008159_53	Waist-to-hip ratio adjusted for BMI	3.000000e-06
GCST90002383_293	Hematocrit	1.000000e-18
GCST90002384_467	Hemoglobin	4.000000e-21

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004305	erythrocyte count
EFO:0004348	hematocrit
EFO:0004343	waist-hip ratio
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0004509	hemoglobin measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5724614 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	2
Valproic Acid	increases methylation, increases expression	2
aristolochic acid I	increases expression	1
TAK-243	increases sumoylation	1
bisphenol A	decreases expression	1
trichostatin A	affects expression	1
beta-lapachone	increases expression	1
butyraldehyde	increases expression	1
coumarin	decreases phosphorylation	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	decreases expression	1
abrine	increases expression	1
LDN 193189	decreases expression, affects cotreatment	1
(+)-JQ1 compound	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Temozolomide	increases expression	1
Vorinostat	increases expression	1
Acetaminophen	increases expression	1
Benzo(a)pyrene	decreases methylation	1
Caffeine	affects phosphorylation	1
Copper	affects binding, decreases expression	1
Disulfiram	affects binding, decreases expression	1
Doxorubicin	decreases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Ivermectin	decreases expression	1
Lead	affects expression	1
Ribonucleotides	affects binding	1
Rotenone	increases expression	1

ChEMBL screening assays

6 unique, capped per target: 6 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5697276	Binding	Inhibition of NOSIP (unknown origin) assessed as fold change at 10 uM incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. — Nature

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3CL	Abcam HEK293T NOSIP KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.